Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo

INTRODUCTION: Trastuzumab is widely used for the treatment of HER2-positive breast cancer. Despite encouraging clinical results, a significant fraction of patients are, or become, refractory to the drug. To overcome this, trastuzumab-DM1 (T-DM1), a newer, more potent drug has been introduced. We tes...

Descripción completa

Detalles Bibliográficos
Autores principales: Barok, Mark, Tanner, Minna, Köninki, Katri, Isola, Jorma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3219209/
https://www.ncbi.nlm.nih.gov/pubmed/21510863
http://dx.doi.org/10.1186/bcr2868

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3219209/
https://www.ncbi.nlm.nih.gov/pubmed/21510863
http://dx.doi.org/10.1186/bcr2868

Ejemplares similares